Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00314158 · ClinicalTrials.gov registry record · Phase 3

A Study of a Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension

A Phase 3 study, sponsored by Alcon Research.

Completed
Registry status
Phase 3
Development phase
523
Enrollment target

NCT00314158 is a Phase 3 study that has completed, run by Alcon Research. The registered enrollment target is 523 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00314158, a Phase 3 study, has completed, sponsored by Alcon Research.

COMPLETED
Registry status
Phase 3
Development phase
523 participants
Enrollment target

Study Summary

The purpose of this study is to determine whether a glaucoma therapy is safe and effective in treating patients with open-angle glaucoma or ocular hypertension.

Interventions

  • DRUG Brinzolamide 10 mg/ml + Timolol 5 mg/ml eye drops, suspension
  • DRUG Brinzolamide 10 mg/ml (AZOPT) eye drops, suspension
  • DRUG Timolol 5 mg/ml eye drops, solution

Trial Details

FieldValue
Enrollment Target 523 participants
Start Date 2005-11
Est. Completion 2007-01
Phase Phase 3

Sponsor

Alcon Research

275 total trials

What the Registry Record Tells You About NCT00314158

The ClinicalTrials.gov registry entry for NCT00314158 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 523 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alcon Research, which has 275 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 3 interventions - of which Brinzolamide 10 mg/ml + Timolol 5 mg/ml eye drops, suspension is the first listed.

NCT00314158 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00314158 about?

NCT00314158 is a clinical study titled "A Study of a Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension". The purpose of this study is to determine whether a glaucoma therapy is safe and effective in treating patients with open-angle glaucoma or ocular hypertension.

What is the current status of trial NCT00314158?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 523 participants. The study started on 2005-11. Estimated completion is 2007-01.

What interventions are being tested in trial NCT00314158?

The interventions under investigation include: Brinzolamide 10 mg/ml + Timolol 5 mg/ml eye drops, suspension (DRUG), Brinzolamide 10 mg/ml (AZOPT) eye drops, suspension (DRUG), Timolol 5 mg/ml eye drops, solution (DRUG).

Who is sponsoring clinical trial NCT00314158?

This trial is sponsored by Alcon Research, which has 275 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.